Study to Investigate if the Uptake of Ticagrelor Into the Body Differs Depending on Method of Administration.
Study Details
Study Description
Brief Summary
Study to investigate if the uptake of Ticagrelor into the body differs depending on method of administration.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 1 |
Detailed Description
Study to evaluate the bioavailability of the crushed ticagrelor tablets when administered orally or through nasogastric tubes compared to whole ticagrelor tablets given orally
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: A Ticagrelor 90 mg as a whole tablet |
Drug: Ticagrelor 90 mg whole tablet
Ticagrelor 90 mg whole tablet administered as a single oral dose
|
| Experimental: B Ticagrelor 90 mg tablet crushed and suspended in water |
Drug: Ticagrelor 90 mg tablet crushed
Ticagrelor 90 mg crushed and suspended in water
|
| Experimental: C Dispersed ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the the stomach |
Drug: Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube
Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
|
Outcome Measures
Primary Outcome Measures
- Description of the pharmacokinetic(PK) profile in terms of plasma concentration-time curve (AUC) of ticagrelor [PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose]
- Description of the pharmacokinetic(PK) profile in terms of AUC of the active metabolite of ticagrelor [PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose]
- Description of the pharmacokinetic(PK) profile in terms of maximum plasma concentration (Cmax) of ticagrelor [PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose]
- Description of the pharmacokinetic(PK) profile in terms of Cmax of the active metabolite of ticagrelor [PK samples will be collected pre-dose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36 and 48 hours post-dose]
Secondary Outcome Measures
- Description of the safety profile in terms of adverse events (AE) [From first dose through to the follow-up visit.]
- Description of the safety profile in terms of laboratory variables [Safety labs at screening, Day -1, Day 3 (48 hours after treatment) and follow-up]
- Description of the safety profile in terms of vital signs [Vital signs at screening, pre-dose, 1 h, 3, 6, 12 and 24 hours post-dose, Day 3 for all treatment periods and follow-up]
- Description of the safety profile in terms of physical examination findings [Physical examination at screening, pre-dose, Day 3 and follow-up]
- Description of the safety profile in terms of Electrocardiogram (ECG) [ECGs at screening, Day 3 and follow-up]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Healthy male and female volunteers aged 18 to 50 years (inclusive) with suitable veins for cannulation or repeated venepuncture
-
Have a body mass index between 18 and 30 kg/m2 (inclusive) and weigh at least 50 kg (110 pounds [lbs]) and no more than 100 kg (220 lbs).
-
Provision of signed and dated, written informed consent prior to any study specific procedures
Exclusion Criteria:
-
History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the volunteer at risk because of participation in the study, or influence the results or the volunteer's ability to participate in the study
-
History of haemophilia, von Willebrand's disease, lupus anticoagulant or other diseases/syndromes that can either alter or increase the propensity for bleeding
-
A personal history of vascular abnormalities including aneurysms; a personal history of severe haemorrhage, haematemesis, melena, haemoptysis, severe epistaxis, severe thrombocytopenia, intracranial haemorrhage; or rectal bleeding within 3 months prior to the screeening visit; or history suggestive of peptic ulcer disease
-
History of frequent and/or significant nose bleed or clinically significant non traumatic bleed, bruise/haematoma or any other clinically significant bleeding risk, as judged by the Investigator
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Research Site | London | United Kingdom |
Sponsors and Collaborators
- AstraZeneca
Investigators
- Study Director: Judith Hsia, MD, AstraZeneca, Wilmington, US
- Study Chair: Mirjana Kujacic, MD, AstraZeneca Mölndal, Sweden
- Principal Investigator: Saeed Kahn, MBBS, Quintiles London, United Kingdom
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- D5130C00076